{"entity": "researcher", "timestamp": "2026-09-28T11:44:19.980Z", "family": "Wedemeyer", "given": "Heiner", "initials": "H", "orcid": "0000-0003-2906-0480", "affiliations": ["Department of Gastroenterology and Hepatology, University of Hannover, Hannover, Germany."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/c7b948fc15a44b329be26ab4cfe44301.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/c7b948fc15a44b329be26ab4cfe44301"}}, "publications": [{"entity": "publication", "iuid": "c5d8462cbfcc422f963ee40c22dd930a", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c5d8462cbfcc422f963ee40c22dd930a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c5d8462cbfcc422f963ee40c22dd930a"}}, "title": "The cascade of care for patients with chronic hepatitis delta in Southern Stockholm, Sweden for the past 30 years.", "authors": [{"family": "Kamal", "given": "Habiba", "initials": "H"}, {"family": "Lindahl", "given": "Karin", "initials": "K"}, {"family": "Ingre", "given": "Michael", "initials": "M"}, {"family": "Gahrton", "given": "Caroline", "initials": "C"}, {"family": "Karkkonen", "given": "Kerstin", "initials": "K"}, {"family": "Nowak", "given": "Piotr", "initials": "P"}, {"family": "Vesterbacka", "given": "Jan", "initials": "J"}, {"family": "St\u00e5l", "given": "Per", "initials": "P"}, {"family": "Wedemeyer", "given": "Heiner", "initials": "H", "orcid": "0000-0003-2906-0480", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c7b948fc15a44b329be26ab4cfe44301.json"}}, {"family": "Duberg", "given": "Ann-Sofi", "initials": "AS"}, {"family": "Aleman", "given": "Soo", "initials": "S"}], "type": "journal article", "published": "2024-01-00", "journal": {"title": "Liver Int.", "issn": "1478-3231", "volume": "44", "issue": "1", "pages": "228-240", "issn-l": "1478-3223"}, "abstract": "Previous studies have shown suboptimal screening for hepatitis D virus (HDV) among patients with chronic hepatitis B (CHB). This study presents the cascade of care for HDV infection in a major secondary referral centre in Southern Stockholm, Sweden.\n\nHBsAg+ve patients attending Karolinska University Hospital (KUH) from 1992 to 2022 were identified. The prevalence of anti-HDV and/or HDV RNA positivity, interferon (IFN) therapy and maintained virological responses (MVR) after HDV treatment were assessed. Also, time to anti-HDV testing was analysed in relation to liver-related outcomes with logistic regression.\n\nAmong 4095 HBsAg+ve persons, 3703 (90.4%) underwent an anti-HDV screening; within a median of 1.8 months (range 0.0-57.1) after CHB diagnosis. This screening rate increased over time, to 97.9% in the last decade. Overall, 310 (8.4%) were anti-HDV+ve, of which 202 (65.2%) were HDV RNA+ve. Eighty-five (42%) received IFN, and 9 (10.6%) achieved MVR at the last follow-up. The predictive factors for anti-HDV screening were Asian origin, diagnosis after the year 2012, HIV co-infection (negative factor) and HBV DNA level < 2000 IU/mL in univariable analysis, while HIV co-infection was the only remaining factor in multivariable analysis. Delayed anti-HDV test >5 years was independently associated with worsened liver-related outcomes (adjusted odds ratio = 7.6, 95% CI 1.8-31.6).\n\nHigher frequency of HDV screening than previously published data could be seen among CHB patients at KUH in a low-endemic setting. Receiving a delayed screening test seems to be associated with worse outcomes, stressing the need of a strategy for timely HDV diagnosis.", "doi": "10.1111/liv.15770", "pmid": "37904316", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T12:18:34.450Z", "modified": "2026-09-23T12:18:34.542Z"}]}